To: Board of Supervisors
From: Anna Roth, Health Services Director
Report Title: Payment for Products and Supplies Provided by Qiagen LLC
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Auditor-Controller or designee, to pay $234,887 to Qiagen LLC for QuantiFERON tubes for use with Contra Costa Health's (CCH) DiaSorin analyzer during the period from January 1, 2024, through April 30, 2024.
FISCAL IMPACT:
Approval of this action will result in a one-time expenditure of up to $234,887 and will be funded by the Hospital Enterprise Fund I.
BACKGROUND:
QuantiFERON tubes are specialized blood collection tubes used in the QuantiFERON-TB Gold Plus test, a blood test used to detect tuberculosis (TB) infection. Due to delays in finalizing the agreement with Qiagen LLC, the lab has continued to purchase QuantiFERON tubes to ensure an uninterrupted supply of patient care.
QuantiFERON testing is crucial for accurately diagnosing and managing TB infection, ensuring appropriate treatment, and reducing the risk of transmission to others.
The vendor is entitled to payment for the reasonable value of the products and supplies under the equitable relief theory of quantum meruit. The theory provides that where a vendor has been asked to provide products and supplies without a valid contract, and the vendor does so to the benefit of the county, the contractor is entitled to recover the reasonable value of those products and supplies. As such, the Department requests that the Board authorize the Auditor-Controller to issue a one-time payment not to exceed $234,887 payable to Qiagen LLC.
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, Qiagen LLC will not be reimbursed for products and supplies already rendered at CCRMC.